Opens in a new tab or window Worries that tumor necrosis factor (TNF) inhibitors may exacerbate or even cause lung disease in patients with rheumatoid arthritis (RA) are unfounded, at least for U ...

Targeted drugs for rheumatoid ... inhibitors reported decreases in pain that were an average of 4.0 points greater (95% CI ...

Positive data in December from Rigel Pharmaceuticals' phase 2 trial of R788, an oral rheumatoid ... an inhibitor of Syk kinase, as a direct challenger to the tumor necrosis factor-alpha (TNF ...

Tumor necrosis factor alpha (TNF α) is involved in cell differentiation, mitogenesis, cytotoxic responses, inflammation, immunomodulation, and wound healing. Because of its numerous roles ...

The price to buy certain infused biosimilars can be three times higher than reimbursement, and the problem is growing.

Rheumatoid arthritis (RA ... Specifically, the efficacy of tumor necrosis factor (TNF) inhibitors was notably impacted by BMI, while other therapies like IL-23 and IL-17 inhibitors showed more ...

Nanjing Reju Therapeutics Inc. has described tumor necrosis factor receptor type 1-associated DEATH domain protein (TRADD) inhibitors reported to be useful for the treatment of inflammatory-related ...

Using glucocorticoids, rituzimab, or certain immunosuppressants to treat connective tissue diseases is associated with greater risks for severe COVID-19-related outcomes.

Investigators used Veterans Administration data to assess the relationship among rheumatoid ... rheumatoid arthritis patients treated with triple therapy or tumor necrosis factor inhibitor.

tumor necrosis factor inhibitors (TNFi). The study grouped 32,098 patients with psoriasis or psoriatic arthritis (PsA) into their respective categories based on biologic treatment, which included ...